港股異動 | 利好疊加 雲康集團(2325.HK)漲約3%再創新高
格隆匯7月5日丨次新股雲康集團(2325.HK)再度拉昇漲約3%,現報18.58港元續刷上市新高價,總市值首次站上115億港元。公司日前和多方公司就設立合資公司訂立合資協議,公司相信合資協議項下的合作將有利於服務網路下沉及擴張、完善市場佈局,並對集團的持續經營產生積極影響。招銀國際首予雲康集團“買入”評級,目標價23.44港元。公司短期收入回報良好的同時,也為拓展共建渠道創造了條件,該行預計該業務將會作為發展的重心,快速擴增,到2024年收入佔比將達到50%,看好未來共建業務的快速增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.